Selective VIP receptor agonists facilitate immune transformation for dopaminergic neuroprotection in MPTP-intoxicated mice

Journal of Neuroscience

Volumn 35, Issue 50, 2015, Pages 16463-16478

  Olson, Katherine E ^a   Kosloski Bilek, Lisa M ^a   Anderson, Kristi M ^a   Diggs, Breha J ^b   Clark, Barbara E ^b   Gledhill, John M ^b   Shandler, Scott J ^b   Mosley, R Lee ^a   Gendelman, Howard E ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b Longevity Biotech   (United States)

Author keywords

Adaptive immunity; Inflammation; Neuroprotection; Parkinson s disease; VIP; VPAC

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 6; LBT 3393; LBT 3627; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE AGONIST; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2; CYTOKINE; LBT-3627; NEUROPROTECTIVE AGENT; OLIGOPEPTIDE; TYROSINE 3 MONOOXYGENASE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1; VIPR1 PROTEIN, MOUSE; VIPR2 PROTEIN, MOUSE;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DOPAMINERGIC TRANSMISSION; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MOUSE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; RNA ISOLATION; SPLEEN CELL; AGONISTS; ANIMAL; C57BL MOUSE; CELL LINE; CHO CELL LINE; CRICETULUS; CYTOLOGY; DOPAMINERGIC NERVE CELL; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HAMSTER; HUMAN; IMMUNOLOGY; METABOLISM; MICROGLIA; MPTP POISONING; PATHOLOGY; PATHOPHYSIOLOGY; SPLEEN; SUBSTANTIA NIGRA;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CHO CELLS; CRICETINAE; CRICETULUS; CYTOKINES; DOPAMINERGIC NEURONS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED C57BL; MICROGLIA; MPTP POISONING; NEUROPROTECTIVE AGENTS; OLIGOPEPTIDES; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE, TYPE II; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; SPLEEN; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 84949949615     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.2131-15.2015     Document Type: Article

References (86)

1. Abad C, Martinez C, Juarranz MG, Arranz A, Leceta J, Delgado M, Gomariz RP (2003) Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn’s disease. Gastroen-terology 124:961-971
2. Abad C, Juarranz Y, Martinez C, Arranz A, Rosignoli F, Garcia-Gómez M, Leceta J, Gomariz RP (2005) cDNA array analysis of cytokines, chemokines, and receptors involved in the development of TNBS-induced coli-tis: homeostatic role of VIP. Inflamm Bowel Dis 11:674-684
3. Abad C, Tan YV, Lopez R, Nobuta H, Dong H, Phan P, Feng JM, Campagnoni AT, Waschek JA (2010) Vasoactive intestinal peptide loss leads to impaired CNS parenchymal T-cell infiltration and resistance to experi-mental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 107: 19555-19560
4. Bas J, Calopa M, Mestre M, Molleví DG, Cutillas B, Ambrosio S, Buendia E (2001) Lymphocyte populations in Parkinson’s disease and in rat models of parkinsonism. J Neuroimmunol 113:146-152
5. Benner EJ, Mosley RL, Destache CJ, Lewis TB, Jackson-Lewis V, Gorantla S, Nemachek C, Green SR, Przedborski S, Gendelman HE (2004) Thera-peutic immunization protects dopaminergic neurons in a mouse model of Parkinson’s disease. Proc Natl Acad Sci U S A 101:9435-9440
6. Benner EJ, Banerjee R, Reynolds AD, Sherman S, Pisarev VM, Tsiperson V, Nemachek C, Ciborowski P, Przedborski S, Mosley RL, Gendelman HE (2008) Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS One 3:e1376
7. Boersma MD, Haase HS, Peterson-Kaufman KJ, Lee EF, Clarke OB, Colman PM, Smith BJ, Horne WS, Fairlie WD, Gellman SH (2012) Evaluation of diverse alpha/beta-backbone patterns for functional alpha-helix mimicry: analogues of the Bim BH3 domain. J Am Chem Soc 134:315-323.
8. Brenneman DE, Foster GA (1987) Structural specificity of peptides influencing neuronal survival during development. Peptides 8:687-694.
9. Brochard V, Combadière B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V, Bonduelle O, Alvarez-Fischer D, Callebert J, Launay JM, Duyckaerts C, Flavell RA, Hirsch EC, Hunot S (2009) Infiltration of CD4 lympho-cytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 119:182-192
10. Cheloha RW, Maeda A, Dean T, Gardella TJ, Gellman SH (2014) Backbone modification of a polypeptide drug alters duration of action in vivo. Nat Biotechnol 32:653-655
11. Chen G, Hao J, Xi Y, Wang W, Wang Z, Li N, Li W (2008) The therapeutic effect of vasoactive intestinal peptide on experimental arthritis is associated with CD4 CD25 T regulatory cells. Scand J Immunol 68:572-578.
12. Chneiweiss H, Glowinski J, Prémont J (1985) Vasoactive intestinal polypeptide receptors linked to an adenylate cyclase, and their relationship with biogenic amine-and somatostatin-sensitive adenylate cyclases on central neuronal and glial cells in primary cultures. J Neurochem 44:779-786.
13. Choi WS, Kruse SE, Palmiter RD, Xia Z (2008) Mitochondrial complex I inhibition is not required for dopaminergic neuron death induced by rotenone, MPP, or paraquat. Proc Natl Acad Sci U S A 105:15136-15141
14. Connolly DJ, O’Neill LA, McGettrick AF (2013) The GOLD domain-containing protein TMED1 is involved in interleukin-33 signaling. J Biol Chem 288:5616-5623
15. Dehay B (2012) New experimental approach for modeling Parkinson’s disease. Mov Disord 27:344
16. Delgado M, Ganea D (2003) Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson’s disease by blocking microglial activation. FASEB J 17:944-946
17. Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D (1999) Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies. J Immunol 162:1707-1716
18. Delgado M, Gomariz RP, Martinez C, Abad C, Leceta J (2000) Anti-inflammatory properties of the type 1 and type 2 vasoactive intestinal peptide receptors: role in lethal endotoxic shock. Eur J Immunol 30: 3236-3246
19. Delgado M, Abad C, Martinez C, Leceta J, Gomariz RP (2001) Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med 7:563-568
20. Delgado M, Gonzalez-Rey E, Ganea D (2004a) VIP/PACAP preferentially attract Th2 effectors through differential regulation of chemokine production by dendritic cells. FASEB J 18:1453-1455
21. Delgado M, Pozo D, Ganea D (2004b) The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol Rev 56:249-290.
22. Delgado M, Chorny A, Gonzalez-Rey E, Ganea D (2005) Vasoactive intesti-nal peptide generates CD4 CD25 regulatory T cells in vivo. J Leukoc Biol 78:1327-1338
23. Deng S, Xi Y, Wang H, Hao J, Niu X, Li W, Tao Y, Chen G (2010) Regulatory effect of vasoactive intestinal peptide on the balance of Treg and Th17 in collagen-induced arthritis. Cell Immunol 265:105-110
24. Dickson L, Finlayson K (2009) VPAC and PAC receptors: From ligands to function. Pharmacol Ther 121:294-316
25. Dogrukol-Ak D, Banks WA, Tunçel N, Tunçel M (2003) Passage of vasoactive intestinal peptide across the blood-brain barrier. Peptides 24: 437-444
26. Domschke S, Domschke W, Bloom SR, Mitznegg P, Mitchell SJ, Lux G, Strunz U (1978) Vasoactive intestinal peptide in man: pharmacokinetics, metabolic and circulatory effects. Gut 19:1049-1053
27. Fernandez-Martin A, Gonzalez-Rey E, Chorny A, Ganea D, Delgado M (2006) Vasoactive intestinal peptide induces regulatory T cells during experimental autoimmune encephalomyelitis. Eur J Immunol 36: 318-326
28. Fiszer U, Mix E, Fredrikson S, Kostulas V, Olsson T, Link H (1994) gamma delta T cells are increased in patients with Parkinson’s disease. J Neurol Sci 121:39-45
29. Fraccaroli L, Grasso E, Hauk V, Paparini D, Soczewski E, Mor G, Pérez Leirós C, Ramhorst R (2015) VIP boosts regulatory T cell induction by trophoblast cells in an in vitro model of trophoblast-maternal leukocyte interaction. J Leukoc Biol 98:49-58
30. Ganea D, Rodriguez R, Delgado M (2003) Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: players in innate and adaptive immunity. Cell Mol Biol 49:127-142
31. Gonzalez-Rey E, Varela N, Chorny A, Delgado M (2007) Therapeutical approaches of vasoactive intestinal peptide as a pleiotropic immunomodulator. Curr Pharm Des 13:1113-1139
32. Gozes I, Brenneman DE (1996) Activity-dependent neurotrophic factor (ADNF): an extracellular neuroprotective chaperonin? J Mol Neurosci 7:235-244
33. Ha D, Stone DK, Mosley RL, Gendelman HE (2012) Immunization strate-gies for Parkinson’s disease. Parkinsonism Relat Disord 18:S218-S221.
34. Hadwen J, MacKenzie D, Shamim F, Mongeon K, Holcik M, MacKenzie A, Farooq F (2014) VPAC2 receptor agonist BAY 55-9837 increases SMN protein levels and moderates disease phenotype in severe spinal muscular atrophy mouse models. Orphanet J Rare Dis 9:4
35. Horne WS, Price JL, Gellman SH (2008) Interplay among side chain sequence, backbone composition, and residue rigidification in polypeptide folding and assembly. Proc Natl Acad Sci U S A 105:9151-9156
36. Hösli E, Hösli L (1989) Autoradiographic localization of binding sites for vasoactive intestinal peptide and angiotensin II on neurons and astrocytes of cultured rat central nervous system. Neuroscience 31:463-470.
37. Huang X, Reynolds AD, Mosley RL, Gendelman HE (2009) CD 4 T cells in the pathobiology of neurodegenerative disorders. J Neuroimmunol 211: 3-15
38. Igarashi H, Ito T, Pradhan TK, Mantey SA, Hou W, Coy DH, Jensen RT (2002a) Elucidation of the vasoactive intestinal peptide pharmacophore for VPAC(2) receptors in human and rat and comparison to the pharma-cophore for VPAC(1) receptors. J Pharmacol Exp Ther 303:445-460.
39. Igarashi H, Ito T, Hou W, Mantey SA, Pradhan TK, Ulrich CD 2nd, Hocart SJ, Coy DH, Jensen RT (2002b) Elucidation of vasoactive intestinal peptide pharmacophore for VPAC(1) receptors in human, rat, and guinea pig. J Pharmacol Exp Ther 301:37-50
40. Jackson-Lewis V, Przedborski S (2007) Protocol for the MPTP mouse model of Parkinson’s disease. Nat Protoc 2:141-151
41. Johnson LM, Gellman SH (2013) alpha-Helix mimicry with alpha/betapeptides. Methods Enzymol 523:407-429
42. Johnson LM, Barrick S, Hager MV, McFedries A, Homan EA, Rabaglia ME, Keller MP, Attie AD, Saghatelian A, Bisello A, Gellman SH (2014) A potent alpha/beta-peptide analogue of GLP-1 with prolonged action in vivo. J Am Chem Soc 136:12848-12851
43. Joo KM, Chung YH, Kim MK, Nam RH, Lee BL, Lee KH, Cha CI (2004) Distribution of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide receptors (VPAC1, VPAC2, and PAC1 re-ceptor) in the rat brain. J Comp Neurol 476:388-413
44. Juarranz Y, Gutiérrez-Cañas I, Santiago B, Carrión M, Pablos JL, Gomariz RP (2008) Differential expression of vasoactive intestinal peptide and its functional receptors in human osteoarthritic and rheumatoid synovial fibroblasts. Arthritis Rheum 58:1086-1095
45. Kelso ML, Elliott BR, Haverland NA, Mosley RL, Gendelman HE (2015) Granulocyte-macrophage colony stimulating factor exerts protective and immunomodulatory effects in cortical trauma. J Neuroimmunol 278: 162-173
46. Kim WK, Kan Y, Ganea D, Hart RP, Gozes I, Jonakait GM (2000) Vasoactive intestinal peptide and pituitary adenylyl cyclase-activating polypeptide inhibit tumor necrosis factor-alpha production in injured spinal cord and in activated microglia via a cAMP-dependent pathway. J Neurosci 20:3622-3630
47. Korendovych IV, Kim YH, Ryan AH, Lear JD, Degrado WF, Shandler SJ (2010) Computational design of a self-assembling beta-peptide oligomer. Org Lett 12:5142-5145
48. Korkmaz O, Ay H, Ulupinar E, Tun ¸el N (2012) Vasoactive intestinal peptide enhances striatal plasticity and prevents dopaminergic cell loss in Parkinsonian rats. J Mol Neurosci 48:565-573
49. Kosloski LM, Ha DM, Hutter JA, Stone DK, Pichler MR, Reynolds AD, Gendelman HE, Mosley RL (2010) Adaptive immune regulation of glial homeostasis as an immunization strategy for neurodegenerative diseases. J Neurochem 114:1261-1276
50. Kosloski LM, Kosmacek EA, Olson KE, Mosley RL, Gendelman HE (2013) GM-CSF induces neuroprotective and anti-inflammatory responses in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxicated mice. J Neuroimmunol 265:1-10
51. Koziorowski D, Tomasiuk R, Szlufik S, Friedman A (2012) Inflammatory cytokines and NT-proCNP in Parkinson’s disease patients. Cytokine 60: 762-766
52. Kroenke MA, Carlson TJ, Andjelkovic AV, Segal BM (2008) IL-12-and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J Exp Med 205:1535-1541
53. Kurkowska-Jastrzebska I, Wrońska A, Kohutnicka M, Czlonkowski A, Czlonkowska A (1999) The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse. Exp Neurol 156:50-61
54. Larocca L, Calafat M, Roca V, Franchi AM, Leirós CP (2007) VIP limits LPS-induced nitric oxide production through IL-10 in NOD mice macrophages. Int Immunopharmacol 7:1343-1349
55. Lee HS, LePlae PR, Porter EA, Gellman SH (2001) Anefficient route to either enantiomer of orthogonally protected trans-3-aminopyrrolidine-4-carboxylic acid. J Org Chem 66:3597-3599
56. McGeer PL, Itagaki S, Akiyama H, McGeer EG (1988) Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol 24: 574-576
57. McLaughlin P, Zhou Y, Ma T, Liu J, Zhang W, Hong JS, Kovacs M, Zhang J (2006) Proteomic analysis of microglial contribution to mouse strain-dependent dopaminergic neurotoxicity. Glia 53:567-582
58. Miyazaki M, Miyazaki K, Chen S, Itoi M, Miller M, Lu LF, Varki N, Chang AN, Broide DH, Murre C (2014) Id2 and Id3 maintain the regulatory T cell pool to suppress inflammatory disease. Nat Immunol 15:767-776.
59. Mosley RL, Benner EJ, Kadiu I, Thomas M, Boska MD, Hasan K, Laurie C, Gendelman HE (2006) Neuroinflammation, oxidative Stress and the pathogenesis of Parkinson’s disease. Clin Neurosci Res 6:261-281.
60. Mosley RL, Hutter-Saunders JA, Stone DK, Gendelman HE (2012) Inflam-mation and adaptive immunity in Parkinson’s disease. Cold Spring Harb Perspect Med 2:a009381
61. Nicole P, Lins L, Rouyer-Fessard C, Drouot C, Fulcrand P, Thomas A, Cou-vineau A, Martinez J, Brasseur R, Laburthe M (2000) Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist: alanine scanning and molecular modeling of the peptide. J Biol Chem 275:24003-24012
62. Nikodemova M, Watters JJ (2012) Efficient isolation of live microglia with preserved phenotypes from adult mouse brain. J Neuroinflammation 9:147
63. O’Donnell M, Garippa RJ, Rinaldi N, Selig WM, Tocker JE, Tannu SA, Was-serman MA, Welton A, Bolin DR (1994a) Ro 25-1553: a novel, longacting vasoactive intestinal peptide agonist. Part II: Effect on in vitro and in vivo models of pulmonary anaphylaxis. J Pharmacol Exp Ther 270: 1289-1294
64. O’Donnell M, Garippa RJ, Rinaldi N, Selig WM, Simko B, Renzetti L, Tannu SA, Wasserman MA, Welton A, Bolin DR (1994b) Ro 25-1553: a novel, long-acting vasoactive intestinal peptide agonist. Part I: In vitro and in vivo bronchodilator studies. J Pharmacol Exp Ther 270:1282-1288.
65. Offen D, Sherki Y, Melamed E, Fridkin M, Brenneman DE, Gozes I (2000) Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson’s disease. Brain Res 854:257-262
66. Otto D, Unsicker K (1993) FGF-2-mediated protection of cultured mesencephalic dopaminergic neurons against MPTP and MPP: specificity and impact of culture conditions, non-dopaminergic neurons, and astroglial cells. J Neurosci Res 34:382-393
67. Pandol SJ, Dharmsathaphorn K, Schoeffield MS, Vale W, Rivier J (1986) Vasoactive intestinal peptide receptor antagonist [4Cl-D-Phe6, Leu17] VIP. Am J Physiol 250:G553-G557
68. Quah BJ, Parish CR (2010) The use of carboxyfluorescein diacetate succinimidyl ester (CFSE) to monitor lymphocyte proliferation. J Vis Exp pii: 2259
69. Reubi JC (2003) Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 24:389-427
70. Reynolds AD, Banerjee R, Liu J, Gendelman HE, Mosley RL (2007) Neuro-protective activities of CD4 CD25 regulatory T cells in an animal model of Parkinson’s disease. J Leukoc Biol 82:1083-1094
71. Reynolds AD, Glanzer JG, Kadiu I, Ricardo-Dukelow M, Chaudhuri A, Ci-borowski P, Cerny R, Gelman B, Thomas MP, Mosley RL, Gendelman HE (2008) Nitrated alpha-synuclein-activated microglial profiling for Parkinson’s disease. J Neurochem 104:1504-1525
72. Reynolds AD, Stone DK, Hutter JA, Benner EJ, Mosley RL, Gendelman HE (2010) Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson’s disease. J Im-munol 184:2261-2271
73. Romero-Ramos M, von Euler Chelpin M, Sanchez-Guajardo V (2014) Vaccination strategies for Parkinson disease: induction of a swift attack or raising tolerance? Hum Vaccin Immunother 10:852-867
74. Saunders JA, Estes KA, Kosloski LM, Allen HE, Dempsey KM, Torres-Russotto DR, Meza JL, Santamaria PM, Bertoni JM, Murman DL, Ali HH, Standaert DG, Mosley RL, Gendelman HE (2012) CD4 regulatory and effector/memory T cell subsets profile motor dysfunction in Parkinson’s disease. J Neuroimmune Pharmacol 7:927-938
75. Schäbitz WR, Kruger C, Pitzer C, Weber D, Laage R, Gassler N, Aronowski J, Mier W, Kirsch F, Dittgen T, Bach A, Sommer C, Schneider A (2008) A neuroprotective function for the hematopoietic protein granulocyte-macrophage colony stimulating factor (GM-CSF). J Cereb Blood Flow Metab 28:29-43
76. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zu-rawski G, Moshrefi M, Qin J, Li X, Gorman DM, Bazan JF, Kastelein RA (2005) IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23:479-490
77. Shandler SJ, Korendovych IV, Moore DT, Smith-Dupont KB, Streu CN, Lit-vinov RI, Billings PC, Gai F, Bennett JS, DeGrado WF (2011) Computational design of a beta-peptide that targets transmembrane helices. J Am Chem Soc 133:12378-12381
78. Tan YV, Abad C, Wang Y, Lopez R, Waschek JA (2015) VPAC2 (vasoactive intestinal peptide receptor type 2) receptor deficient mice develop exacerbated experimental autoimmune encephalomyelitis with increased Th1/Th17 and reduced Th2/Treg responses. Brain Behav Immun 44: 167-175
79. Tunçel N, Korkmaz OT, Tekin N, Şener E, Akyuz F, Inal M (2012) Antioxidant and anti-apoptotic activity of vasoactive intestinal peptide (VIP) against 6-hydroxy dopamine toxicity in the rat corpus striatum. J Mol Neurosci 46:51-57
80. Usdin TB, Bonner TI, Mezey E (1994) Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology 135:2662-2680
81. Vial T, Descotes J (1995) Clinical toxicity of cytokines used as haemopoietic growth factors. Drug Saf 13:371-406
82. Voice J, Donnelly S, Dorsam G, Dolganov G, Paul S, Goetzl EJ (2004) c-Maf and JunB mediation of Th2 differentiation induced by the type 2 G protein-coupled receptor (VPAC2) for vasoactive intestinal peptide. J Immunol 172:7289-7296
83. Volpicelli-Daley LA, Luk KC, Patel TP, Tanik SA, Riddle DM, Stieber A, Meaney DF, Trojanowski JQ, Lee VM (2011) Exogenous alphasynuclein fibrils induce Lewy body pathology leading to synaptic dysfunc-tion and neuron death. Neuron 72:57-71
84. Waschek JA (2013) VIP and PACAP: neuropeptide modulators of CNS inflammation, injury, and repair. Br J Pharmacol 169:512-523
85. Yadav M, Rosenbaum J, Goetzl EJ (2008) Cutting edge: vasoactive intestinal peptide (VIP) induces differentiation of Th17 cells with a distinctive cytokine profile. J Immunol 180:2772-2776
86. Yadav M, Huang MC, Goetzl EJ (2011) VPAC1 (vasoactive intestinal peptide (VIP) receptor type 1) G protein-coupled receptor mediation of VIP enhancement of murine experimental colitis. Cell Immunol 267: 124-132